rtx1 Adaptive Optics Retinal Camera
Regulatory approved medical device in several countries
2-second acquisitions
No compromise on patient comfort
Track diseases at the microscopic scale in the retina
"In follow-up examinations of AMD patients, the rtx1 enabled detecting the progression of atrophic lesions over a timescale of weeks, instead of months with conventional imaging."
Prof. Paques. Quinze-Vingts National Hospital, June 2020, Paris, France
"AO technology will likely contribute to faster and more cost effective drug development for the treatment of eye diseases."
Lin et al.
Invest Opth Vis Sc 2019, 60:4520-4531
"Adaptive optics (AO) ophthalmoscopy is now an accessible tool to visualize photoreceptors in the human living retina."
Cristescu et al.
Rom J Ophthalmol. 2019, 63:153-160.
"The rtx1 allowed us to directly observe stem-cell-derived RPE cells after their transplantation in a patient’s retina. We could verify that the mosaic arrangement of these cells was similar to that of natural RPE cells, and stable over time."
Dr. Takagi. Kobe City Eye Center, July 2019, Kobe, Japan
"Direct assessment of photoreceptors in RP patients by high-resolution imaging technologies is crucial for the future development of RP therapeutics."
Lin et al.
Invest Opth Vis Sc 2019, 60:4520-4531
"Several studies of human retinal photoreceptors in diabetic patients using Imagine Eyes’ AO retinal camera have been achieved."
Cristescu et al.
Rom J Ophthalmol. 2019, 63:153-160.
"The rtx1 demonstrates that, unlike the common belief, performing AO retinal imaging can be as easy as standard retinal imaging."
Prof. Paques.
Quinze-Vingt National Hospital, July 2018, Paris, France
"We, for the first time, visualized longitudinal changes during the recovery of cone photoreceptors in the eyes of VKH patients."
Nakamura et al.
Graefes Arch Clin Exp Ophthalmol 2018, 256:387-394
"The image resolution achieved by this technology is superior to that of any other current diagnostic tool."
Zaleska-Zmijewska et al.
Journal of Diabetes Research 2017, article ID 4174292
"Adaptive optics retinal imaging provided non-invasive and sensitive information on the pathologic disruption of the cone mosaic."
Ziccardi et al.
American J Ophthalmol 2015, 160:301-312
Imaging at the cellular level
When using the rtx1 Adaptive Optics Retinal Camera, you examine the retina at a scale where individual cells are visible. It reveals parafoveal cone photoreceptors as well as other microscopic retinal structures that cannot be seen with conventional techniques, thanks to a 10 times better resolution.
Microvascular imaging
The rtx1 enables visualizing the microscopic walls of retinal arterioles non-invasively. Focal narrowing, perivascular sheathing, micro-hemorrhages and micro-aneurisms are also visible without using contrast agents.
Imaging the retinal pigment epithelium
The TFI add-on module extends the imaging capability of rtx1 for investigating retinal anatomy, pathology and therapy. Using transscleral illumination, rtx1-TFI enables visualizations of otherwise invisible microscopic detail in the retinal pigment epithelium, as well as pigment redistribution in retinal degeneration.
Most existing rtx1 units can be upgraded with the TFI module.
Protocol workflows
Designed for multicenter trials
Fast follow-up exams
Micrometric progressions revealed
Cellular & vascular biomarkers
Fast annotations and analyzes
Large-field AO images
Automated montage with DualAlign®
Over 250 publications
Extensively validated technology
Reference product
The rtx1 stands out as the most widely-used AO imaging device throughout the world. Cleared by regulatory authorities in several countries, and adopted by 90 clinical centers, it has become the reference device for cellular-level retinal assessments in clinical research. More than 250 publications illustrate the extensive clinical knowledge and findings that users of the rtx1 AO camera have gained in a large variety of diseases that impact the retina.
Fast protocol workflows
Designed in collaboration with clinicians, the rtx1 enables comfortable and quick examination for high patient throughput.
The Protocols functionality guides users through every step of virtually any imaging procedure. It enables accelerating and standardizing AO examinations in multicenter studies.
Tracking microscopic progression/regression
By design, the rtx1 delivers images that are free from motion distortion. Building on this advantage, the software makes it easy to capture multiple regions of interest through different visits, and automatically registers follow-up images. This allows tracking minute changes in groups of cells, vessels, or lesions over time.
Cellular biomarkers
With AOdetect application, rtx1 delivers an array of candidate biomarkers for assessing the distribution of parafoveal cone cells, as well as RPE cells on TFI images :
- Voronoi cell density
- Inter-cell spacing
- Regularity index
- Dispersion index
On follow-up images, AOdetect enables analyzing the exact same region of interest, for monitoring a given group of cells over time.
Microvascular biomarkers
AOdetect application also provides supervised image segmentation for analyzing the wall morphology of blood vessels. With this option, rtx1 delivers non-invasive vascular structure metrics with micrometer precision:
- Internal and external diameter
- Wall thickness
- Wall Cross Section Area (WSCA)
- Wall to Lumen Ratio (WLR)
The exact same vascular section is assessed on follow-up images with a only a few clicks.
Explore neurovascular coupling
Flicker stimulation with rtx1 enables micron-precision assessments of neurovascular response in health conditions and diseases that affect small blood vessels.
Deeper insight in retinal microstructure
The rtx1 software provides protocols for investigating alterations in the directional reflectance of retinal microscopic structures.
Gaze-dependent imaging enables visualizations of small drusen with enhanced contrast (figure: Rossi et al., TVST 2021).
Incidence-dependent imaging allows exploring pathological changes in photoreceptor reflectance, in relation with the stiles-cawford effect.
Large field AO images in 1 click
rtx1 images are compatible with the ultra-fast stiching algorithms from DualAlign®. With i2k Retina AO™ software, effortlessly assemble multiple AO images into high quality montages.
Downloads & links
Specifications
| Imaging type | En face reflectance imaging |
| Detection type | Low-noise CCD camera |
| Illumination | Near infrared LED, 850nm |
| Exposure time | < 10 ms |
| Imaging field of view 1 | 4° x 4° |
| Fixation stimulation range | H ± 14.5° / V ± 10° |
| Camera pixel pitch on the fundus 1 | 1.1 µm |
| Optical resolution on the fundus 1, 2 | 250 line pairs per millimeter (lppmm) |
| Adaptive optics control | Fully automated, resistant to blinking and movement |
| Depth focussing range 1 | 1600 µm |
| Pupil diameter | ≥ 4 mm |
| Refractive error compensation | -12 to +6 D |
| Total footprint (WxDxH) | 137x53x132-162 cm |
1 Some specifications are dependent on several factors including but not limited to: ocular biometry, pupil diameter, optical defects, ocular media transparency.
2 The system can image line pairs of 2 µm in line width.
rtx1 is a certified medical device of class IIa in the European Union. rtx1 is an approved medical device in Japan, China and Korea. In the USA, rtx1 has not received FDA clearance; it is an investigational device that requires Institutional Review Board (IRB) oversight.
rtx1 with AOdetect is certified in the European Union, Japan and Korea. rtx1 with TFI is certified in the European Union.
In other territories, rtx1 with AOdetect or TFI are for research use only.
For use by trained eyecare professionals only.
All retinal images on this page are courtesy of: Quinze-Vingts National Eye Hospital, Paris, France.
i2k is not part of the rtx1 product. i2k has not been approved for clinical use. It is for research use only. DualAlign, i2k, i2k Retina AO are trademarks of DualAlign LLC.